VRTX in the 13F filings
Vertex Pharmaceuticals Inc · CUSIP 92532F100
- Quarter end
- 30 Jun 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 30 Jul 2025
- Managers listing it
- 21
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q1 2025 and Q2 2025; 18 listed it in both
- Shares listed
- 72,575,296
- combined, among listed positions
- Reported value
- $32.3bn
- combined, at the quarter end
Among the 95 comparable managers: 11 buyers (opened or added shares) and 11 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing VRTX in Q2 2025
21 of 21 holders
Largest increases and reductions, by shares
Increases
- Capital Research Global Investorsexisting position · 16,108,291 shares now+1,571,947
- AllianceBernstein LPexisting position · 4,378,320 shares now+424,808
- T. Rowe Price Associates Incexisting position · 3,159,870 shares now+242,643
- Capital World Investorsexisting position · 28,732,143 shares now+198,835
- Invesco Ltdexisting position · 1,984,046 shares now+138,406
Reductions
- Fidelity (FMR LLC)existing position · 6,406,372 shares now-1,320,812
- MFS Investment Managementexisting position · 1,284,354 shares now-740,554
- Wellington Management Group LLPexisting position · 4,813,386 shares now-641,362
- Renaissance Technologies LLCexisting position · 1,004,888 shares now-166,683
- Janus Henderson Group Ltdexisting position · 2,619,534 shares now-128,403
New positions and exits
New (1)
Exited (1)
- Element Capital Management LLCwas $2.6m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 13 | $5.0bn | n.a. | n.a. |
| Q3 2013 | 12 | $4.6bn | n.a. | n.a. |
| Q4 2013 | 9 | $4.8bn | n.a. | n.a. |
| Q1 2014 | 11 | $4.9bn | n.a. | n.a. |
| Q2 2014 | 11 | $7.3bn | n.a. | n.a. |
| Q3 2014 | 14 | $9.0bn | n.a. | n.a. |
| Q4 2014 | 15 | $9.3bn | n.a. | n.a. |
| Q1 2015 | 21 | $9.2bn | n.a. | n.a. |
| Q2 2015 | 23 | $9.4bn | n.a. | n.a. |
| Q3 2015 | 22 | $8.3bn | n.a. | n.a. |
| Q4 2015 | 19 | $10.2bn | n.a. | n.a. |
| Q1 2016 | 18 | $6.8bn | n.a. | n.a. |
| Q2 2016 | 13 | $7.5bn | n.a. | n.a. |
| Q3 2016 | 14 | $7.7bn | n.a. | n.a. |
| Q4 2016 | 14 | $6.3bn | n.a. | n.a. |
| Q1 2017 | 21 | $9.5bn | n.a. | n.a. |
| Q2 2017 | 24 | $11.0bn | n.a. | n.a. |
| Q3 2017 | 28 | $12.6bn | n.a. | n.a. |
| Q4 2017 | 24 | $12.2bn | n.a. | n.a. |
| Q1 2018 | 24 | $13.3bn | n.a. | n.a. |
| Q2 2018 | 27 | $14.0bn | n.a. | n.a. |
| Q3 2018 | 26 | $15.7bn | n.a. | n.a. |
| Q4 2018 | 27 | $14.6bn | n.a. | n.a. |
| Q1 2019 | 26 | $17.0bn | n.a. | n.a. |
| Q2 2019 | 24 | $17.0bn | n.a. | n.a. |
| Q3 2019 | 25 | $16.0bn | n.a. | n.a. |
| Q4 2019 | 29 | $20.0bn | n.a. | n.a. |
| Q1 2020 | 27 | $20.9bn | n.a. | n.a. |
| Q2 2020 | 27 | $23.4bn | n.a. | n.a. |
| Q3 2020 | 31 | $21.9bn | n.a. | n.a. |
| Q4 2020 | 30 | $18.4bn | n.a. | n.a. |
| Q1 2021 | 31 | $15.4bn | n.a. | n.a. |
| Q2 2021 | 30 | $12.7bn | n.a. | n.a. |
| Q3 2021 | 35 | $10.1bn | n.a. | n.a. |
| Q4 2021 | 28 | $12.4bn | n.a. | n.a. |
| Q1 2022 | 23 | $16.1bn | n.a. | n.a. |
| Q2 2022 | 25 | $18.1bn | n.a. | n.a. |
| Q3 2022 | 22 | $18.4bn | n.a. | n.a. |
| Q4 2022 | 28 | $18.4bn | n.a. | n.a. |
| Q1 2023 | 26 | $21.4bn | n.a. | n.a. |
| Q2 2023 | 27 | $24.7bn | n.a. | n.a. |
| Q3 2023 | 33 | $24.3bn | n.a. | n.a. |
| Q4 2023 | 32 | $28.6bn | 16 | 16 |
| Q1 2024 | 31 | $29.8bn | 16 | 19 |
| Q2 2024 | 29 | $33.4bn | 12 | 18 |
| Q3 2024 | 27 | $33.5bn | 17 | 10 |
| Q4 2024 | 26 | $28.5bn | 14 | 13 |
| Q1 2025 | 21 | $35.4bn | 10 | 11 |
| Q2 2025 | 21 | $32.3bn | 11 | 11 |
| Q3 2025 | 22 | $25.9bn | 13 | 10 |
| Q4 2025 | 26 | $31.8bn | 19 | 20 |
| Q1 2026 | 25 | $31.8bn | 17 | 21 |
| Q2 2026 | 26 | $34.6bn | 21 | 17 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
VRTX and LLY →VRTX and JNJ →VRTX and GILD →Choose a stock to compare with VRTX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own VRTX, latest filings →Back to the 13F Explorer →